In a von Willebrand disease workup, what does a low activated partial thromboplastin time, elevated factor VIII activity, high ristocetin cofactor activity, and negative von Willebrand factor antigen indicate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

This Laboratory Pattern Does Not Match Any Recognized Von Willebrand Disease Subtype

The combination of low aPTT, high factor VIII, high ristocetin cofactor activity, but negative (absent) von Willebrand antigen is internally inconsistent and likely represents a laboratory error or pre-analytical issue that requires immediate specimen recollection and repeat testing. 1

Why This Pattern is Impossible

This constellation of results violates fundamental hemostatic biology:

  • Von Willebrand factor antigen (VWF:Ag) is the protein itself - if it's truly absent/negative, there can be no ristocetin cofactor activity to measure, as ristocetin cofactor activity measures the functional ability of VWF protein to bind platelets 1

  • Factor VIII requires VWF as a carrier protein - without VWF antigen present, factor VIII would be rapidly degraded and levels would be low, not high 1, 2

  • aPTT would be prolonged, not low - if VWF:Ag were truly absent (as in type 3 VWD), factor VIII would be markedly reduced (<3%), causing a significantly prolonged aPTT, not a shortened one 1, 2

Likely Explanations for This Result Pattern

Pre-analytical Errors (Most Common):

  • Sample mix-up - results from different patients
  • Improper specimen collection - hemolysis, lipemia, or clotted sample
  • Timing issues - VWF levels are acute phase reactants and can be elevated by stress, inflammation, pregnancy, or estrogen 2, 3
  • Assay interference - particularly with the VWF:Ag immunoassay

Technical Laboratory Issues:

  • Different reference ranges between assays causing misinterpretation
  • Assay-specific problems - the older VWF:RCo assay has known issues with reproducibility and false results 1

Immediate Action Required

Repeat the entire von Willebrand screen with a fresh specimen, ensuring:

  • Proper collection technique (avoid hemolysis)
  • Patient is not acutely stressed or inflamed
  • Use of newer VWF activity assays (VWF:GPIbM or VWF:GPIbR) rather than the problematic VWF:RCo assay 1
  • Verification that all tests are from the same specimen

What Normal VWD Patterns Should Look Like

According to current 2025 guidelines 1:

  • Type 1 VWD: VWF:Ag ↓, VWF activity ↓ (proportionate), Factor VIII normal to ↓, aPTT normal to prolonged
  • Type 2 variants: VWF:Ag normal to ↓, VWF activity ↓↓ (disproportionate), Factor VIII normal to ↓
  • Type 3 VWD: VWF:Ag ↓↓↓ (absent), VWF activity ↓↓↓ (absent), Factor VIII ↓↓↓, aPTT markedly prolonged

No recognized VWD subtype presents with absent VWF:Ag but high ristocetin cofactor and high factor VIII - this combination is biologically implausible and mandates investigation for laboratory error before any clinical interpretation.

References

1
Guideline

diagnosis of von willebrand disease.

Blood advances, 2025

2
Research

Screening and diagnosis of coagulation disorders.

American journal of obstetrics and gynecology, 1996

Related Questions

In a 4‑month‑old infant with non‑traumatic petechiae on the medial aspects of both femurs and laboratory findings of normal platelet count, normal prothrombin time (PT), normal activated partial thromboplastin time (aPTT), normal von Willebrand factor (vWF) antigen, reduced von Willebrand factor activity (~40 %), and normal factor VIII, what is the appropriate next step in management?
In a 6-year-old boy with recurrent epistaxis, von Willebrand factor antigen 62%, von Willebrand factor activity 80%, normal factor VIII, normal prothrombin time (PT) and activated partial thromboplastin time (aPTT), what is the best management approach?
What is the best screening test and diagnostic cascade for children with mild von Willebrand disease?
What laboratory tests and treatments are recommended for patients suspected of having a blood clotting disorder?
What findings would be expected on the peripheral blood smear of a 29-year-old woman presenting with bleeding gums and thrombocytopenia?
What are the factors influencing patellar tracking in total knee arthroplasty?
What is the hepatitis B status for a patient with hepatitis B surface antibody positive, hepatitis B surface antigen negative, total hepatitis B core antibody positive, and hepatitis B core IgM antibody negative?
What dietary recommendations should be included in a patient handout for individuals taking GLP‑1 receptor agonist therapy (e.g., exenatide, liraglutide, dulaglutide, semaglutide)?
What equations are used to estimate the osmolarity of parenteral nutrition (PN) solutions?
What dietary recommendations should be provided to adult patients undergoing Zepbound (tirzepatide) therapy for weight loss?
What is the appropriate management for a patient presenting with septic shock, acute kidney injury, high anion‑gap metabolic acidosis, lactic acidosis, coagulopathy, and decompensated heart failure based on the provided laboratory results?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.